-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Orthopoxvirus
- Others
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Virus Protease
- Antiviral intermediates
Sparstolonin-B
![{PARAM:[Name]}()](https://resource.bocsci.com/structure/1259330-61-4.gif)
| Category | Human immunodeficiency Virus (HIV) |
| CAS | 1259330-61-4 |
| Description | Sparstolonin B acts as a selective TLR2 and TLR4 antagonist and selectively blocks TLR2- and TLR4-mediated inflammatory signaling. Sparstolonin B has anti-HIV and anticancer activities. |
Product Information
| Synonyms | sparstolonin B|1259330-61-4|4,14-dihydroxy-8,15-dioxatetracyclo[7.7.1.02,7.013,17]heptadeca-1(16),2(7),3,5,9(17),10,13-heptaen-12-one|SCHEMBL16158994|Sparstolonin B, >=98% (HPLC)|HY-116213|CS-0064377 |
| Molecular Weight | 268.22 |
| Molecular Formula | C15H8O5 |
| Canonical SMILES | C1=CC2=C(C=C1O)C3=COC(=C4C3=C(O2)C=CC4=O)O |
| Purity | ≥98% (HPLC) |
| Solubility | In vitro: 10 mM in DMSO |
| Appearance | Light yellow to yellow (Solid) |
| Storage | Powder: -20°C: 3 years 4°C: 2 years In solvent: -80°C: 6 months -20°C: 1 month |
| Complexity | 622 |
| Exact Mass | 268.03717335 |
| In Vitro | Sparstolonin B (1-20 µM; 2-4 days) inhibits cell growth and viability of neuroblastoma cells. Sparstolonin B inhibits TLR ligand-induced cytokine expression in mouse macrophages. Sparstolonin B inhibits MyD88 recruitment to TLR4 and TLR2. Sparstolonin B generates reactive oxygen species (ROS) in neuroblastoma cells. Sparstolonin B reduces expression of N-myc in neuroblastoma cells. Cell Viability Assay Cell Line: SH-SY5Y, IMR-32, NGP, SKNF-1 and SK-N-BE(2) cells Concentration: 1 µM, 5 µM, 10 µM or 20 µM Incubation Time: 2-4 days Result: Effectively and dose-dependently inhibits the viability of all neuroblastoma cell lines after 2 days (SH-SY5Y and IMR-32), 3 days (NGP cells) or 4 days (SKNF-1 and SK-N-BE(2) cells) treatment. |
| In Vivo | Sparstolonin B (100 μg/mouse; i.p.) suppresses LPS-provoked inflammation in mice. Animal Model: 5-6-week-old male C57Bl/6 mice (body weight 18-20 g) Dosage: 100 μg/mouse Administration: I.p. Result: Significantly lower TNFα and IL-1β expression levels in LPS-induced sepsis mouse model. |
| Target | Toll-like Receptor (TLR); HIV |
| XLogP3-AA | 1.5 |
